Key Information
Source
summary/abstract
The report highlights the urgent need to improve recognition, diagnosis and care for people living with heart failure with preserved ejection fraction (HFpEF) and transthyretin amyloid cardiomyopathy (ATTR-CM) — conditions that remain under-recognised within current care pathways.
Heart failure affects an estimated 1 million people in the UK, with a further 400,000 living undiagnosed. Around half of all heart failure patients have HFpEF, and ATTR-CM is estimated to be an underlying cause in 11% of these cases, often following a long and complex diagnostic journey.